… The goals of the analysis were to identify the landscape of ctDNA across pathological
subtypes, to evaluate the prevalence of clinically actionable alterations, to compare blood and …

… as a prognostic marker can be applied to both early and metastatic breast cancer disease
as suggested by subgroup analysis in this study. Another potential benefit of ctDNA is that it …

… serial circulating tumor DNA (ctDNA) testing for predicting pCR and risk of metastatic recurrence.
… In summary, our study shows promise that early response prediction by highly sensitive …

… The high sensitivity of ctDNA testing for tissue mutations calls into question the need … ctDNA
results, within the pretreated metastatic breast cancer patient population studied. This study …

… early changes of circulating tumor DNA (ctDNA) levels … study were to evaluate the relationship
between ctDNA detection and variation from baseline (bsl) to D15 and D30 with the tumor …

… of ctDNA in breast cancer. There are two fundamental strategies to analyze ctDNA: (1)
Quantification of total cfDNA based on the notion that cancer cells release more DNA than healthy …

… Detection of circulating tumor DNA (ctDNA) after neoadjuvant … stage breast cancer may
allow for early detection of relapse. In this study, we analyzed ctDNA using a personalized, tumor-…

… that tumor heterogeneity can be noninvasively assessed through circulating tumor DNA (ctDNA).14-…
treatment outcome using tumor heterogeneity in ctDNA of metastatic breast cancer. …

… Circulating tumor DNA (ctDNA), identified based on the presence of somatic mutations, can
… that breast DNA could be detected in the circulation of patients with metastatic breast cancer, …

… that the detection of circulating tumor DNA (ctDNA) in blood is strongly associated with
poor prognosis (15,16). Contemporaneous analysis of CTCs and ctDNA in MBC have been …